Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis
03/04/2025 13:06
April 3 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA: ENLIVEX ANNOUNCES THE DOSING OF THE FIRST PATIENT IN A PHASE I TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH TMJ OSTEOARTHRITIS Source text: ID:nGNX85VLZr Further company coverage: ENLV.TA (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment